Pediatrix Medical Group Future Growth
Future criteria checks 3/6
Pediatrix Medical Group is forecast to grow earnings and revenue by 95.2% and 0.01% per annum respectively. EPS is expected to grow by 83.1% per annum. Return on equity is forecast to be 15.2% in 3 years.
Key information
95.2%
Earnings growth rate
83.1%
EPS growth rate
| Healthcare earnings growth | 17.4% |
| Revenue growth rate | 0.006% |
| Future return on equity | 15.2% |
| Analyst coverage | Good |
| Last updated | 27 Jan 2025 |
Recent future growth updates
Recent updates
Returns At Pediatrix Medical Group (NYSE:MD) Are On The Way Up
Jan 28
Pediatrix Medical Group: The Business Is Turning
Nov 18Pediatrix Medical Group, Inc. (NYSE:MD) Shares Fly 27% But Investors Aren't Buying For Growth
Nov 06Here's Why Pediatrix Medical Group (NYSE:MD) Has A Meaningful Debt Burden
Oct 19We Like These Underlying Return On Capital Trends At Pediatrix Medical Group (NYSE:MD)
Sep 28Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified
Aug 07Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Jun 19Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger
May 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking
Mar 29Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 10Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors
Dec 25Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Nov 14Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?
Oct 13Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?
Aug 09Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold
Aug 08At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?
Jul 03The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing
Jun 08Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet
Apr 26Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?
Feb 20Pediatrix Medical Group Q4 2022 Earnings Preview
Feb 16Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?
Jan 12Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold
Dec 22Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing
Dec 20Pediatrix appoints James Swift as chief executive officer
Dec 15Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Nov 05Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M
Nov 03Pediatrix: These 5 Graphs Suggest It's A Buy
Sep 29Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly
Sep 13Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return
Aug 29Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching
Jul 27Pediatrix: Seeking 46% Return Objective As Speculative Buy
Jul 14MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 24MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet
May 25Return Trends At MEDNAX (NYSE:MD) Aren't Appealing
Apr 20MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 2,076 | 106 | N/A | N/A | 1 |
| 12/31/2026 | 2,001 | 121 | N/A | N/A | 6 |
| 12/31/2025 | 1,944 | 115 | 131 | 162 | 8 |
| 12/31/2024 | 1,997 | -17 | 102 | 136 | 8 |
| 9/30/2024 | 2,007 | -254 | 115 | 143 | N/A |
| 6/30/2024 | 2,002 | -252 | 100 | 131 | N/A |
| 3/31/2024 | 1,999 | -71 | 81 | 113 | N/A |
| 12/31/2023 | 1,995 | -60 | 104 | 137 | N/A |
| 9/30/2023 | 2,012 | 88 | 133 | 167 | N/A |
| 6/30/2023 | 1,995 | 95 | 139 | 170 | N/A |
| 3/31/2023 | 1,981 | 98 | 134 | 164 | N/A |
| 12/31/2022 | 1,972 | 63 | 137 | 167 | N/A |
| 9/30/2022 | 1,957 | 79 | 89 | 112 | N/A |
| 6/30/2022 | 1,960 | 82 | 63 | 90 | N/A |
| 3/31/2022 | 1,947 | 82 | 31 | 61 | N/A |
| 12/31/2021 | 1,911 | 108 | 44 | 77 | N/A |
| 9/30/2021 | 1,829 | 72 | -15 | 21 | N/A |
| 6/30/2021 | 1,797 | 38 | 99 | 129 | N/A |
| 3/31/2021 | 1,739 | 14 | 236 | 264 | N/A |
| 12/31/2020 | 1,734 | -10 | 176 | 205 | N/A |
| 9/30/2020 | 1,776 | -4 | 326 | 352 | N/A |
| 6/30/2020 | 1,770 | 11 | 321 | 341 | N/A |
| 3/31/2020 | 1,678 | 1 | 261 | 284 | N/A |
| 12/31/2019 | 1,780 | 42 | 338 | 358 | N/A |
| 9/30/2019 | 2,210 | 94 | 331 | 351 | N/A |
| 6/30/2019 | 2,603 | 143 | 292 | 320 | N/A |
| 3/31/2019 | 3,145 | 221 | 296 | 324 | N/A |
| 12/31/2018 | 1,723 | 122 | 297 | 314 | N/A |
| 9/30/2018 | 3,477 | 333 | 303 | 346 | N/A |
| 6/30/2018 | 3,497 | 337 | N/A | 417 | N/A |
| 3/31/2018 | 3,475 | 326 | N/A | 420 | N/A |
| 12/31/2017 | 3,253 | 305 | N/A | 498 | N/A |
| 9/30/2017 | 3,378 | 262 | N/A | 447 | N/A |
| 6/30/2017 | 3,337 | 293 | N/A | 443 | N/A |
| 3/31/2017 | 3,266 | 312 | N/A | 455 | N/A |
| 12/31/2016 | 3,183 | 325 | N/A | 444 | N/A |
| 9/30/2016 | 3,094 | 340 | N/A | 417 | N/A |
| 6/30/2016 | 2,988 | 334 | N/A | 393 | N/A |
| 3/31/2016 | 2,893 | 336 | N/A | 389 | N/A |
| 12/31/2015 | 2,780 | 336 | N/A | 369 | N/A |
| 9/30/2015 | 2,689 | 332 | N/A | 443 | N/A |
| 6/30/2015 | 2,593 | 327 | N/A | 431 | N/A |
| 3/31/2015 | 2,512 | 322 | N/A | 419 | N/A |
| 12/31/2014 | 2,439 | 317 | N/A | 423 | N/A |
| 9/30/2014 | 2,356 | 308 | N/A | 383 | N/A |
| 6/30/2014 | 2,284 | 299 | N/A | 382 | N/A |
| 3/31/2014 | 2,218 | 289 | N/A | 374 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: MD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MD is expected to become profitable in the next 3 years.
Revenue vs Market: MD's revenue (0.01% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: MD's revenue (0.01% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MD's Return on Equity is forecast to be low in 3 years time (15.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 03:03 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pediatrix Medical Group, Inc. is covered by 31 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Gillmor | Baird |
| James Kumpel | BB&T Capital Markets |